Kewaunee Scientific Q1 sales fall 6.7%; diluted EPS $0.58 vs. $1.04
Kewaunee Scientific reported first-quarter fiscal 2027 sales of $66.3 million, down 6.7% from a year earlier, and diluted earnings per share of $0.58 versus $1.04. Pre-tax earnings fell 34.7%, partly due to extra compensation expense from settling long-term incentive awards in cash, which the company says will not recur. Backlog rose from April 30, 2026 but remained below its level a year earlier.
Key points
- Sales were $66.3 million versus $71.1 million; net earnings attributable to the company were $1.7 million versus $3.1 million.
- Pre-tax earnings were $2.6 million versus $3.9 million, a decrease of 34.7%.
- Backlog rose to $169.0 million on July 31, 2026, from $165.9 million on April 30, 2026, but was $205.0 million on July 31, 2025.
- Long-term debt excluding the sale-leaseback obligation fell to $13.8 million from $15.1 million on April 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.